MILAN (ITALPRESS) – There are nearly 21 thousand victims of cardiovascular disease in Campania, the second highest number of cardiovascular-related deaths in Italy. A health priority in the region, with more than 1.3 million people at risk of developing a cardiovascular event and nearly 800 thousand Campanians with LDL cholesterol levels above the recommended 1. Revealing this scenario are the results of the Health CaRe report conducted by the Interdepartmental Center for Research in Pharmacoeconomics and Pharmacoutization (CIRFF) of the Federico II University of Naples in collaboration with the Health Protection DG of the Campania Region, with the aim of identifying Campania patients with chronic conditions and in particular those with high-risk cardiovascular diseases, in terms of prevalence, therapeutic adherence and hospitalization costs. To curb this emergency, a joint working table between Novartis Italy and the Campania Region has been announced to implement secondary prevention programs aimed at Campania patients at high cardiovascular risk. Affecting these numbers are unhealthy lifestyles, which seem to be particularly prevalent: more than 1 in 2 Campania citizens do not exercise and are overweight, and as many as 8 in 10 have never measured their “bad” cholesterol (LDL)3, an important indicator of cardiovascular risk.According to the report, more than 2 million Campania residents – 37.7 percent of the population – have been diagnosed with at least one chronic disease, and cardiovascular disease is among the most prevalent chronic conditions in the region – 17.6 percent of the population – with an increased risk of mortality. The analysis showed a very high cardiovascular risk for 184,135 citizens, but revealed low adherence to statin therapy (36.3 percent non-adherent) and a high number of people with hyperlipidemia (12.2 percent of the population), one of the alarm bells of cardiovascular risk.”Prevention is a priority at the center of the Campania Region’s commitment to reduce the impact of disease on the territory,” said President Vincenzo De Luca. “The picture that emerged from the Health CaRe report on the population at cardiovascular risk confirms how important it is to activate new models and effective management strategies that take into account the complex dynamics that govern the diagnosis, treatment and follow-up of citizens at risk, in order to be able to reduce the likelihood of recurrence and improve long-term clinical outcomes.”We are proud to be able to make our scientific expertise available to the Campania Region, to help address a real health emergency of our times, which heavily affects people’s lives and the sustainability of the System,” comments Valentino Confalone, Country President of Novartis Italy. “As a company, we are convinced that collaboration between the public and private sectors is fundamental to foster the emergence of new models of value-based medicine, oriented to bring concrete benefits to people’s health, overcoming a compartmentalized vision and activating the important synergy between sustainability and innovation.This collaboration between Novartis and the Campania Region will be developed from the results of the Real World analysis and will enable the implementation of new pathways of care and management for Campania’s patients at high cardiovascular risk, so as to reduce regional mortality rates for these diseases, which are now the main cause of hospitalization and death in the territory. These efforts are in addition to actions already underway in the region to reduce the impact of chronic diseases. The goal is to implement multidisciplinary, therapeutic and risk factor monitoring interventions throughout the Campania region, so as to identify those at high risk of disease early and simplify-thanks to new digital technologies-organizational pathways, improving patient care, appropriateness and adherence to treatment.Campania is a strategic region for Novartis, a company highly focused on innovation, which has a presence in Torre Annunziata with the Novartis Life Science Campus that in 2023 generated 5.7 billion euros in pharmaceutical exports to 118 countries, including China, and represents a hub of manufacturing excellence throughout southern Italy. A new 1,000-square-meter production area of the plant was inaugurated in February 2024, adding to the 150,000 square meters already occupied by the campus, which will be dedicated to innovative technologies for the production of new drugs.- Photo source www.pexels.com -(ITALPRESS).
